A recent subgroup analysis of the DAPA-HF study investigated possible clinical outcome differences between women and men following the addition of dapagliflozin to their treatment regimens.
Women and men with heart failure with reduced ejection fraction (HFrEF)—all participants in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial—similarly benefited from the addition of dapagliflozin to their treatment regimens.
Diabetes status did not affect these results, according to the findings published recently in JAMA Cardiology.
Women with HF generally have a greater disease burden and they have been shown to benefit less from treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors, of which dapagliflozin is one. However, this class has also proven itself in recent years as “a valuable treatment for HFrEF, and it is clearly important to examine the effects of this therapy in women as well as men with HFrEF,” the authors noted.
The 4744 patients included in this analysis (23.4% women), with a primary outcome of worsening HF (eg, hospitalization or urgent visit with intravenous therapy) or cardiovascular death, had New York Heart Association functional class II through IV disease and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. They were randomized to an addition of either 10-mg one-daily dapagliflozin or placebo.
Dapagliflozin was shown to similarly lessen the risk of worsening HF events or CV death in men and women:
The SGLT2 inhibitor also resulted in there being more patients with meaningful symptom improvement and fewer with worsening symptoms vs placebo, respectively, as measured by the Kansas City Cardiomyopathy Questionnaire total symptom score:
Treatment discontinuation and the rate of serious adverse events, too, were consistent among the men (mean [SD] age, 65.9 [10.9] years) and women (mean age, 67.6 [10.7] years).
The women in the study tended to be older and Black. They also had a lesser likelihood of atrial fibrillation, chronic obstructive pulmonary disease, and anemia, but a greater chance of having higher systolic blood pressure, heart rate, and baseline NT-proBNP.
Analyses also found:
In addition, systolic blood pressure similarly decreased in both patient groups. At the 4-month mark, this amounted to –1.69 mm Hg (95% CI, –3.37 to –0.02) for the women and –1.88 mm Hg (95% CI, –2.80 to –0.96) for the men.
“Dapagliflozin reduced the risk of worsening HF, cardiovascular death, and all-cause death and improved symptoms, physical function, and health-related quality of life similarly in men and women with heart failure and reduced ejection fraction,” the authors concluded. “Collectively, these data provide further support for dapagliflozin as a new treatment option for HFrEF.”
Importantly, the authors highlight that their finding should offer reassurance that dapagliflozin is tolerable and safe for use among patients with HFrEF, women and men.
Reference
Butt JH, Docherty KF, Petrie MC, et al. Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiol. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0379
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More